Skip to main content
SpringerLink
Log in

Stereotaktisch ablative Bestrahlung als Standardtechnik beim NSCLC im Stadium I bestätigt

Stereotactic ablative radiotherapy confirmed as a standard technique in NSCLC stage I

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–1076

    Article  CAS  Google Scholar 

  2. Nyman J, Hallqvist A, Lund JA et al (2016) SPACE—a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol 121:1–8

    Article  Google Scholar 

  3. Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833–4839

    Article  Google Scholar 

  4. Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Strahlenklinik Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Deutschland

    Markus Hecht &  Rainer Fietkau

Authors
  1. Markus Hecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rainer Fietkau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Hecht.

Ethics declarations

Interessenkonflikt

M. Hecht und R. Fietkau geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Ball D, Mai GT, Vinod S et al; TROG 09.02 CHISEL investigators (2019) Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer: a phase III, open-label, randomised controlled trial. Lancet Oncol 20:494–503

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hecht, M., Fietkau, R. Stereotaktisch ablative Bestrahlung als Standardtechnik beim NSCLC im Stadium I bestätigt. Strahlenther Onkol 195, 945–948 (2019). https://doi.org/10.1007/s00066-019-01503-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-019-01503-z

Search

Navigation